Prevention of Nausea in Migraines Study

Evanston Premier Healthcare Research


Do you have acute migraines?

If so, you may qualify for a multicenter, randomized, double-blind, comparator-controlled, placebo-controlled study to assess the efficacy and safety of oral CL-H1T in the treatment of acute migraine pain, with or without aura, and the prevention of migraine-associated nausea and vomiting (MANV).

You may qualify if:

    You are male or female ages 18 to 65.

    You have a history of episodic migraine for at least 1 year.

    You have 2 to 8 migraine attacks per month; at least 48 hours of headache-free time between migraine attacks.

    You have a history of migraine headache with nausea more than 50% of the time.

Please fill out the form below and we will contact you.

    Your Name (required)

    Your Email Address (required)
    Your email address will be used exclusively to contact you regarding our studies.

    Your telephone number


    Your Message